Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 9Lymphoma, Mantle-Cell 8Breast Neoplasms 7Lymphoma 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Lymphoma, T-Cell 5Lymphoma, Non-Hodgkin 5Lymphoma, Large B-Cell, Diffuse 5Lymphoma, Follicular 5Lymphoma, B-Cell, Marginal Zone 5Lymphoma, B-Cell 5Recurrence 4Neuroblastoma 4Myelodysplastic Syndromes 4Mycosis Fungoides 4Multiple Myeloma 4Lymphoma, T-Cell, Cutaneous 4Leukemia 4Congenital Abnormalities 4Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Leukemia, Myelomonocytic, Acute 3Leukemia, Monocytic, Acute 3Leukemia, Megakaryoblastic, Acute 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Erythroblastic, Acute 3Glioblastoma 3Burkitt Lymphoma 3

Interventions

relatlimab 2linrodostat 2Nivolumab 2Ipilimumab 2Vorinostat 1Trastuzumab 1IFL protocol 1Gemcitabine 1Dasatinib 1Cetuximab 1BMS-813160 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Cancer × Vorinostat × Clear all
NCT00907738 2015-05-21

A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)

Merck Sharp & Dohme LLC

Phase 2 Completed
27 enrolled 9 charts

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡